Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen… - The Lancet, 2013 - thelancet.com
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …
被引用次数：918 相关文章

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon, P Arias… - The …, 2013 - cuk.elsevierpure.com
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen… - The Lancet, 2013 - infona.pl
Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type
2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of …

[引用][C] Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results …

WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen… - The Lancet, 2013 - cir.nii.ac.jp
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes
inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised …

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon, P Arias… - Lancet (London …, 2013 - europepmc.org
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen… - The Lancet, 2013 - thelancet.com
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …

[引用][C] Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results …

WT CEFALU, LA LEITER, KH YOON… - Lancet (British …, 2013 - pascal-francis.inist.fr
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes
inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised …

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen… - The Lancet, 2013 - Elsevier
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …

WT Cefalu, LA Leiter, KH Yoon… - Lancet (London …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …

[引用][C] Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results …

WT CEFALU, LA LEITER, KH YOON, P ARIAS… - Lancet, 2013 - Elsevier